[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"signs-and-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:signs-and-symptoms":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,61,94,127,159,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":43,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100612800","safety-and-clinical-performance-of-the-freesolve-resorbable-magnesium-scaffold-rms-system-in-subjects-with-coronary-artery-lesions-100612800",false,"NCT07258290","Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions","Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries","BIOMAG-III","Clinical Inclusion Criteria:\n\n1. Subject is ≥ 18 years and ≤ 80 years of age\n2. Subject has provided written informed consent as approved by the Ethics Committee \u002F Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures\n3. Subject is eligible for PCI according to the applicable guidelines\n4. Subject is an acceptable candidate for coronary artery bypass surgery\n5. Subjects with stable or unstable angina pectoris, documented silent ischemia\u002Fabnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion\n\n   Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:\n   * Subject and target lesion(s) meet all inclusion and no exclusion criteria and consent occurs at least ≥ 72 hours after successful treatment of the culprit lesion(s) \\[lesion(s) causing the acute STEMI\\];\n   * Subject is hemodynamically stable with documented declining cardiac biomarkers;\n   * Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)\n6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine\n7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)\n8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study\n\nAngiographic Inclusion Criteria:\n\n1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries\n2. Target vessel must have a reference diameter between 2.5-4.2 mm by operator visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) \u002F Intravascular Ultrasound (IVUS) \u002F Optical Coherence Tomography (OCT)\n3. Target lesion(s) must be ≤ 36 mm in length by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT, (or \\\u003C 20 mm for target lesion(s) to be treated with a study device \\\u003C 3.0 mm in diameter) and must be amenable to treatment with a single study device\n4. Target lesion stenosis ≥ 50% and \\\u003C 100% by operator visual estimation, which may be assisted by QCA \u002F IVUS \u002F OCT. Target lesion stenosis \\\u003C 70% by visual estimation, should have clinical justification for treatment as per local standards.\n5. Target lesion must have a Thrombolysis in Myocardial Infarction (TIMI) flow ≥ 1\n\nClinical Exclusion Criteria:\n\n1. Subject is pregnant and\u002For breastfeeding or intends to become pregnant during the duration of the study\n2. Subject has clinical symptoms and\u002For electrocardiogram (ECG) changes consistent with STEMI \\\u003C 72 hours prior to the index procedure Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment\n3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel \\\u003C 72 hours prior to the index procedure\n4. Subject is on dialysis or has impaired renal function (serum creatinine \\> 2.5 mg\u002FdL or 221 µmol\u002FL, determined within 7 days prior to the index procedure)\n5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminum, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, methacrylic polymer, and fluoropolymer)\n6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)\n7. Life expectancy less than 1 year\n8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained\n9. In the investigator's opinion subject will not be able to comply with the follow-up requirements\n10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e., triple therapy) can be maintained for a minimum of 1 month\n11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure\n12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT\n13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug\n14. Subject has known severe aortic or mitral valve stenosis\u002Finsufficiency or has previously undergone transcatheter aortic valve replacement (TAVR)\n\nAngiographic Exclusion Criteria:\n\n1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion\n2. Left main coronary artery disease\n3. Target lesion is totally occluded (100% stenosis)\n4. Thrombus in target vessel\n5. Future planned staged PCI either in target or non-target vessel\n6. Ostial target lesion within the left anterior descending (LAD), left circumflex (LCX), or right coronary artery (RCA) (within 5.0 mm of vessel origin)\n7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation\n8. Target lesion is located in or supplied by an arterial or venous bypass graft\n9. Target lesion with excessive tortuosity proximal to or within the lesion based on visual estimation or heavily calcified target lesion which cannot be adequately pre-dilated by a non-compliant and\u002For cutting\u002Fscoring balloon as described in angiographic exclusion criteria 10\n10. Target lesion requires treatment with a device other than the non-compliant balloon and\u002For cutting\u002Fscoring balloon prior to scaffold\u002Fstent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons, etc.)\n11. Target vessel was treated with brachytherapy any time prior to the index procedure.\n12. Unsuccessful pre-dilatation, defined as residual stenosis \\> 20% (by visual estimation) and\u002For angiographic complications (e.g., distal embolization, side branch closure, flow-limiting dissections)","ALL","18 Years","80 Years",{"count":21,"type":22},1859,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to assess the safety and efficacy of the Freesolve resorbable magnesium scaffold (RMS) in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to the Xience coronary drug-eluting stent (DES) system",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Coronary Disease","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Arterial Occlusive Diseases","Vascular Diseases","Chest Pain","Pain","Neurologic Manifestations","Signs and Symptoms","Pathological Conditions, Signs and Symptoms","Coronary Artery Disease","Myocardial Ischemia","Acute Coronary Syndrome","Angina Pectoris",[44,45,46,47],"Resorbable Magnesium Scaffold","Sirolimus","RMS","Drug eluting absorbable metal scaffold","RECRUITING","2026-06-15",{"date":51,"type":52},"2026-06-17","ACTUAL",{"date":54,"type":52},"2026-06-11",{"date":56,"type":22},"2033-06",{"name":58,"class":59},"Teleflex","INDUSTRY",1,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":80,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":60},"100637454","biomedical-signal-extraction-from-symptom-descriptions-an-observational-registry-using-the-opengenome-platform-100637454","NCT07578610","Biomedical Signal Extraction From Symptom Descriptions: An Observational Registry Using the OpenGenome Platform","Accuracy and Calibration of Evidence-Grounded Biomedical Signal Extraction From Free-Text Symptom Descriptions: A Prospective Observational Registry Using the OpenGenome Automated Research Instrument","OGNOME-REG","* Automated or programmatically generated submissions detected by rate limiting\n* Submissions containing no discernible symptom or health-related content",true,{"count":71,"type":22},1000,"OBSERVATIONAL","This registry prospectively collects anonymized free-text symptom descriptions submitted voluntarily by adults through the OpenGenome platform at opengenome.bio. For each submission, the system retrieves real biomedical literature from PubMed and ClinicalTrials.gov in parallel, applies a constrained reasoning model operating under a strict output schema, and returns a structured biological signal report. The study evaluates the internal consistency of extracted signals, the calibration of confidence scores relative to dataset size and symptom specificity, and the distribution of biological signal categories across a large anonymous population. No intervention is assigned. No participant contact occurs. All data is anonymized at the point of collection.",[37,75,76,77,78,79],"Fever","Myalgia","Skin Diseases","Hemorrhagic Fever With Renal Syndrome","Zoonoses",[81,82,83],"biomedical signal extraction","symptom analysis","PubMed","2026-05-16",{"date":86,"type":52},"2026-05-19",{"date":88,"type":52},"2026-05-05",{"date":90,"type":22},"2028-05-30",{"name":92,"class":93},"OpenGenome","NETWORK",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":113,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":60},"100627679","selective-activation-of-the-adrenomedullin-receptors-in-migraine-100627679","NCT07451769","Selective Activation of the Adrenomedullin Receptors in Migraine","Selective Activation of the Adrenomedullin Receptors in Migraine: A Randomized, Double-Blind, Placebo-Controlled Crossover Study","Inclusion Criteria:\n\n1. Written informed consent has been obtained prior to the initiation of any study-specific procedures.\n2. Age ≥18 years at the time of screening.\n3. History of migraine without aura for at least 12 months prior to screening, with a frequency of 1-5 migraine attacks per month, based on medical records and\u002For patient self-report, and diagnosed in accordance with the ICHD-3 criteria.\n\nExclusion Criteria:\n\n1. History of any other primary headache disorder, except for tension-type headache with \\\u003C5 headache days per month, based on ICHD-3 classification.\n2. History of any secondary headache disorder, per ICHD-3 criteria, prior to screening.\n3. Use of prophylactic migraine medication within 30 days or within 5 plasma half-lives (whichever is longer) prior to screening.\n4. Previous use of any therapies targeting the CGRP signaling pathway, including anti-CGRP ligand monoclonal antibodies, anti-CGRP receptor monoclonal antibodies, or small molecule CGRP receptor antagonists.\n5. Known risk of self-harm or harm to others, including a history of suicidal behavior.\n6. Any clinically significant disorder, condition, or disease (other than those permitted in the protocol) that, in the opinion of the investigator, could compromise participant safety or interfere with study procedures or data integrity.\n7. Positive urine pregnancy test at screening or on Day 1 in female participants of childbearing potential.\n8. Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study period.\n9. Evidence of current pregnancy or breastfeeding based on self-report or medical records.\n10. Inability or unwillingness to complete all protocol-required visits and procedures, or concerns regarding protocol adherence, as judged by the investigator.","65 Years",{"count":103,"type":22},26,[25],"Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.",[107,108,109,110,35,111,112,37],"Migraine","Brain Diseases","Central Nervous System Diseases","Adrenomedullin","Peptides","Neuropeptides",[114,115,35],"Migraine Disorders","Adrenomedulin","NOT_YET_RECRUITING","2026-03-05",{"date":119,"type":52},"2026-03-09",{"date":121,"type":22},"2026-03-10",{"date":123,"type":22},"2032-12-20",{"name":125,"class":126},"Danish Headache Center","OTHER",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":149,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":60},"100619142","hypersensitivity-to-amylin-in-post-traumatic-headache-100619142","NCT07340775","Hypersensitivity to Amylin in Post-Traumatic Headache","Hypersensitivity to Amylin in Post-Traumatic Headache: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* ≥ 4 monthly headache days on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* \\> 1 mild traumatic injury to the head\n* History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)\n* History of moderate or severe injury to the head\n* History of whiplash injury\n* History of craniotomy\n* History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion\n* Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start\n* Baseline headache intensity of \\>3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)\n* Baseline migraine-like headache or self-reported baseline headache that mimics the subjects' usual migraine-like headache",{"count":135,"type":22},21,[25],"Pramlintide is a peptide analogue of human amylin which is a vasoactive substance involved in the pathogenesis of headache. This study investigates whether pramlintide induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).",[139,108,140,141,109,36,37,38,142,35,143,144,145,111,146,147,148],"Headache Disorders, Secondary","Headache Disorders","Nervous System Diseases","Post-Traumatic Headache","Peptide Hormones","Hormones","Hormones, Hormone Substitutes, and Hormone Antagonists","Amino Acids, Peptides, and Proteins","Amylin","Pramlintide",[150,35,147],"Post-traumatic headache","2026-01-05",{"date":153,"type":52},"2026-01-14",{"date":155,"type":22},"2026-02",{"date":157,"type":22},"2028-12",{"name":125,"class":126},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":101,"enrollmentInfo":166,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":60},"100619143","amylin-induced-migraine-attacks-without-aura-100619143","NCT07340788","Amylin-Induced Migraine Attacks Without Aura","Amylin-Induced Migraine Attacks Without Aura: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Age 18 to 65 years of age upon entry into screening\n* A body weight of 50 to 100 kg\n* History of migraine without aura for ≥12 months and in accordance with ICHD-3\n* Between 1-5 monthly migraine days without aura on average across the 3 months prior to screening\n* Provision of informed consent prior to initiation of any study-specific activities\u002Fprocedures\n\nExclusion Criteria:\n\n* Any history of a primary or secondary headache disorder other than migraine without aura and infrequent episodic tension-type headache\n* Any history of moderate to severe traumatic brain injury\n* Any history of cardiovascular disease, including cerebrovascular diseases\n* Any history of pulmonary disease\n* Any other clinically significant disorders, conditions, or diseases that might impact the safety of the subject or interfere with the study's evaluation, procedures, or completion, aside from those mentioned above. This includes any relevant medical history or evidence that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior\n* Female subjects of childbearing potential with a positive pregnancy test during any study visit\n* Cardiovascular disease of any kind, including cerebrovascular diseases\n* Hypertension (systolic blood pressure of ≥150 mmHg and\u002For diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day\n* Hypotension (systolic blood pressure of ≤90 mmHg and\u002For diastolic blood pressure of ≤50 mmHg)\n* Abnormalities on the electrocardiogram that, in the opinion of the site investigator, might pose a risk to the subject or impact the validity of the study results\n* Daily use of any medication other than contraceptives\n* Intake of any medication other than contraceptives within 48 hours of infusion start\n* Intake of caffeine, nicotine, and alcohol within 12 hours of infusion start\n* Headache of any intensity within 48 hours of infusion start\n* Migraine attack within 48 hours of infusion start\n* Aura within 48 hours of infusion start",{"count":135,"type":22},[25],"Pramlintide is a peptide analogue of human amylin which is a vasoactive signaling molecule involved in the pathogenesis of migraine. This study investigates whether pramlintide induces migraine attacks without aura in people with migraine without aura.",[170,140,108,141,109,36,37,38,114,171,35,143,144,145,111,146,147,148],"Headache Disorders, Primary","Headache",[107,171,35,147],{"date":153,"type":52},{"date":155,"type":22},{"date":176,"type":22},"2028-10-30",{"name":125,"class":126},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":23,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100384702","phase-4-cognitive-outcomes-after-dexmedetomidine-sedation-in-cardiac-surgery-patients-100384702","NCT04289142","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients","Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial","CODEX","Inclusion Criteria:\n\n* Planned CABG (+\u002F- valve, including off-pump) or valve replacement via sternotomy\u002Fthoracotomy, with initial recovery in the Cardiovascular Intensive Care Unit (CVICU)\n* Age ≥60\n\nExclusion Criteria:\n\n* Lack of patient consent\n* Pre-operative major cognitive dysfunction (CogState Brief Battery score \\\u003C 80) at screening\n* Aortic arch replacement\u002Fre-implantation (surgery requiring hypothermic circulatory arrest, e.g. Bentall procedure)\n* Allergy\u002Fcontraindication to dexmedetomidine (untreated 2nd degree type 2 or 3rd degree heart block (pacemaker), cirrhosis, HR \\\u003C 50 , grade 4 LV, renal failure or on renal replacement therapy)\n* Unlikely to comply with study assessments (e.g. no fixed address, cannot complete cognitive tests at the 3, 6, and 12 month time points)","60 Years",{"count":188,"type":22},2400,[190],"PHASE4","Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.",[193,194,195,196,197,198,199,36,141,37,200,201,202,203,204,205,206],"Delirium","Cognitive Dysfunction","Cognition Disorder","Neurocognitive Disorders","Mental Disorders","Confusion","Neurobehavioral Manifestations","Dexmedetomidine","Hypnotics and Sedatives","Central Nervous System Depressants","Physiological Effects of Drugs","Analgesics, Non-Narcotic","Analgesics","Molecular Mechanisms of Pharmacological Action","2025-11-27",{"date":209,"type":52},"2025-12-01",{"date":211,"type":52},"2019-12-01",{"date":213,"type":22},"2029-03",{"name":215,"class":126},"Sunnybrook Health Sciences Centre",8]